Paul J. Pockros
Research Subjects
Research Interests
Paul J. Pockros has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
M.S. Sulkowski
3 shared publicationsM.W. Fried
3 shared publicationsA.J. Muir
2 shared publicationsAndrea Duchini
Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
2 shared publicationsD.R. Nelson
2 shared publicationsG.T. Everson
2 shared publications
Latest Publications
- 17 December 2015
- Published by Taylor & Francis in Future Virology
- Vol. 11 (2) , 121-126
Daclatasvir in Hcv Genotype 1 and 3 Treatment
Daclatasvir (DCV) is a novel pan-genotypic nonstructural protein 5A (NS5A) inhibitor recently approved in the USA for treatment of genotype 3 HCV infection (GT3). GT3 HCV has been difficult to treat with direct-acting antivirals. DCV has an increasing database of evidence to show its efficacy against this genotype. In this review, we discuss the pharmacology of DCV and explore the clinical data to support its recent US FDA approval.
- 17 December 2015
- Published by Taylor & Francis in Future Virology
- Vol. 11 (2) , 121-126
Daclatasvir in Hcv Genotype 1 and 3 Treatment
Daclatasvir (DCV) is a novel pan-genotypic nonstructural protein 5A (NS5A) inhibitor recently approved in the USA for treatment of genotype 3 HCV infection (GT3). GT3 HCV has been difficult to treat with direct-acting antivirals. DCV has an increasing database of evidence to show its efficacy against this genotype. In this review, we discuss the pharmacology of DCV and explore the clinical data to support its recent US FDA approval.
- 30 April 2009
- Published by Elsevier in Journal of Hepatology
- Vol. 50, S230-S231
627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES
- 30 April 2009
- Published by Elsevier in Journal of Hepatology
- Vol. 50, S230-S231
627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES
- 1 February 2005
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 7 (1) , 61-70
Helminthic infections of the liver
Human helminthic infestation is exceedingly common on a global scale, with as many as 1.5 to 2 billion people affected worldwide. Helminths (parasitic worms) that infect the liver and hepatobiliary system include nematodes (roundworms), cestodes (tapeworms), and trematodes (flatworms or flukes). The majority of morbidity and mortality from these infestations is caused by the host immune response to the larvae or adult worm. Helminthic disease manifestations vary from the extremes of asymptomatic carriage to cirrhosis and decompensated liver disease. Current basic science and clinical research focus on improvements in medical therapy, mass screening and chemoprophylaxis, and the development of preventative vaccine strategies.
- 1 February 2005
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 7 (1) , 61-70
Helminthic infections of the liver
Human helminthic infestation is exceedingly common on a global scale, with as many as 1.5 to 2 billion people affected worldwide. Helminths (parasitic worms) that infect the liver and hepatobiliary system include nematodes (roundworms), cestodes (tapeworms), and trematodes (flatworms or flukes). The majority of morbidity and mortality from these infestations is caused by the host immune response to the larvae or adult worm. Helminthic disease manifestations vary from the extremes of asymptomatic carriage to cirrhosis and decompensated liver disease. Current basic science and clinical research focus on improvements in medical therapy, mass screening and chemoprophylaxis, and the development of preventative vaccine strategies.
- Open Access
- 24 November 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (6) , 1450-1458
Epoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy
Anemia and decreased health–related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV–infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8–week double–blind phase (DBP), followed by an 8–week open–label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV–infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion , epoetin alfa provided clinically significant HRQL improvement in HCV–infected patients receiving IFN/RBV therapy. (Hepatology 2004;40:1450-1458.)
- 24 November 2004
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (6) , 1450-1458
Open AccessEpoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy
Anemia and decreased health–related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV–infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8–week double–blind phase (DBP), followed by an 8–week open–label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV–infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion , epoetin alfa provided clinically significant HRQL improvement in HCV–infected patients receiving IFN/RBV therapy. (Hepatology 2004;40:1450-1458.)
- 21 October 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (9) , 917-929
The management of side‐effects during therapy for hepatitis C
Summary: The results of interferon and ribavirin combination therapy for chronic hepatitis C infection have substantially improved in recent years, such that the majority of patients in randomized‐controlled trials now achieve a sustained virological response. However, adverse effects are commonplace, often disabling and may lead to interruption or cessation of therapy with subsequent loss of efficacy. Constitutional, neuropsychiatric and haematological reactions have proved particularly troublesome. In this review, we discuss these adverse effects in more detail and highlight recent advances in their management.
- 21 October 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (9) , 917-929
The management of side‐effects during therapy for hepatitis C
Summary: The results of interferon and ribavirin combination therapy for chronic hepatitis C infection have substantially improved in recent years, such that the majority of patients in randomized‐controlled trials now achieve a sustained virological response. However, adverse effects are commonplace, often disabling and may lead to interruption or cessation of therapy with subsequent loss of efficacy. Constitutional, neuropsychiatric and haematological reactions have proved particularly troublesome. In this review, we discuss these adverse effects in more detail and highlight recent advances in their management.